藥物成份

共有 21670 個藥物成份

Phosphate-buffered Saline with Polymer Enhancer 2LSodium Azide (preservative) <0.1% (w/w)

關聯藥證數量: 1

Phosphate-buffered low ionic strength solution (LISS)Each vial contains 0.03M sodium chloride, glycine, glucose, phosphate, a nucleoside and a purine as well as the preservatives chloramphenicol, thrimethoprim and sulfamethoxazole.

關聯藥證數量: 1

Phosphate-buffered saline 2LSodium Azide (preservative) <0.1% (w/w)

關聯藥證數量: 1

Phosphoenolpyruvate:≥40 mmol/L; NADH analog: ≥2 mmol/L; \nMDH (porcine): ≥314.3 μkat/L; PEPC(microbial): ≥30.8μkat/L\n

關聯藥證數量: 1

Phospholipid Antigen-coated polystyrene microwell strips, 1 x 8 wells\nSample Diluent 55 ml/bottle\nIgG Calibrator #1-6 at concentration of 200,100,50,25,12.5 and 6.5 GPL, 1.0 mL for each vial.\nIgM Calibrator #1-6 at concentration of 200,100,50,25,12.5 and 6.5 GPL, 1.0 mL for each vial.\nIgG Conjugate 15 ml/bottle\nIgM Conjugate 15 ml/bottle\nTMB Substrate 30 ml/bottle\nStopping Solution 30 ml/bottle\nPBS Concentrate 15 ml/bottle\nNegative Control 100 ul/vial\nIgG Positive Control 100 ul/vial\nIgM Positive Control 100 ul/vial\n\n

關聯藥證數量: 1

Phosphorus Liqui-UV® Reagent:\nAmmonium molybdate, 0.8 mmol/L, with a reaction accelerator in a acidic solution. \n\n

關聯藥證數量: 1

Phytohaemagglutinin：A freeze dried prepaation of aqueous extraction from selected seed beans of phaseolus spp.

關聯藥證數量: 1

Phytonadione is a mixture of E and Z isomers containing not less than 97.0% and not more than 103.0% of C31H46O2. It contains not more than 21.0% of the Z isomer.

關聯藥證數量: 1

Picric Acid 10 mmol/L\nSodium Hydroxide 260 mmol/L\nSurfactants \n

關聯藥證數量: 1

Picric Acid 10mmol/L\nSodium Hydroxide 260mmol/L\nSurfactants pH 13.0+-0.2 at 25C

關聯藥證數量: 1

Picric Acid 8.1 mmol/L\nBuffered to > 13.3\nAlso non-reactive chemicals necessary for optimal system performance.\n

關聯藥證數量: 1

Picric Acid: 8.1 mmol/L\nBuffered to pH: > 13.3\n

關聯藥證數量: 1

Picric acid 10 mmol/L\nSodium hydroxide 260 mmol/L\nSurfactants

關聯藥證數量: 1

Pigment, binders, buffer, surfactants and cross-linking agent.

關聯藥證數量: 1

Pigment, binders, surfactants, buffer and stabilizer.

關聯藥證數量: 1

Pilocarpine Hydrochloride contains NLT 99% and NMT101% of C11H16N2O2‧HCl, calculated on the dried basis.

關聯藥證數量: 1

Pilocarpine Hydrochloride contains not less than 99.0% and not more than 101.0% of C11H16N2O2•HCl calculated on dried substance.

關聯藥證數量: 1

Pinaverium Bromide contains not less than 99.0% and not more than 101.0% of C26H41Br2NO4, calculated on dried basis.

關聯藥證數量: 1

Pinaverium Bromide contains not less than 99.0% and not more than 101.0% of C26H41NO4Br2, calculated with reference to the anhydrous and solvent-free substance.

關聯藥證數量: 1

Pioglitazone Hydrochloride contains NLT 98.0% and NMT 102.0% of C19H20N2O3S˙HCl, calculated on the anhydrous basis.

關聯藥證數量: 1

Pioglitazone Hydrochloride contains NLT 98.0% and NMT 102.0% of C19H20N2O3S．HCl, calculated on the anhydrous basis.

關聯藥證數量: 1

Pioglitazone Hydrochloride contains not less than 98.0% and not more than 102.0% of C19H20N2O3S‧HCl, calculated on the anhydrous basis.

關聯藥證數量: 1

Pioglitazone Hydrochloride contains not less than 99.0% and not more than 101.0% of C19H20N2O3S.HCl, calculated on dried basis.

關聯藥證數量: 1

Pioglitazone Hydrochloride, when dried,contains between 98% and 102% of C19H20N2O3S .HCl

關聯藥證數量: 1

Piolitazone Hydrochloride contains not less than 98.0% and not more than 102% of C19H20N2O3S？HCl, calculated on the dried basis.

關聯藥證數量: 1

Pipemidic Acid Hydrate

關聯藥證數量: 1

Pipemidic Acid, when dried,contains not less than 98.5% of C14H17N5O3

關聯藥證數量: 1

Piperacillin Sodium Sterile has a potency equivalent to not less than 863μg and not more than 1007μg of piperacillin (C23H27N5O7S) per mg, calculated on the anhydrous basis.

關聯藥證數量: 1

Piperacillin Sodium and Tazobactam Sodium(8:1) contain： - Not less than 80.7% and not more than 86.7% of piperacillin, calculated on the dried basis. - Not less than 9.8% and not more than 10.8% of tazobactam, calculated on the dried basis. - Not less than 84.1% and not more than 90.4% of piperacillin sodium, calculated on the dried basis. - Not less than 10.5% and not more than 11.6% of tazobactam sodium, calculated on the dried basis.

關聯藥證數量: 1

Piperacillin Sodium has a potency equivalent to not less than 863 μg and not more than 1007 μg of piperacillin (C23H27N5O7S) per mg, calculated on the anhydrous basis.

關聯藥證數量: 1

Piperacillin sodium as equivalent to Piperacillin 2g, 4g\nTazobactam sodium as equivalent to Tazobactam 0.25g, 0.5g

關聯藥證數量: 1

Pipes Buffer 80 mmol/l,pH6.8\n4-Aminoantipyrine 0.25 mmol/l\nPhenol 6 mmol/l\nPeroxidase(E.C.1.11.1.7,Horse Radish,+25℃) ≧0.5 U/ml\nCholesterol esterase(E.C.3.1.1.13. Pseudomonas,37℃) ≧0.2 U/ml\nCholesterol oxidase(E.C.1.1.3.6 Nocardia, 37℃) ≧0.10 U/ml\n

關聯藥證數量: 1

Pipes buffer 50mmol/l\np-Chlorophenole 2 mmol/l\nLipoprotein Lipase 150000 U/l\nGlycerokinase 800 U/l\nGlycerol-3-P-oxidase 4000 U/l\nPeroxidase 440 U/l\n4-Aminoantipyrine 0.7 mmol/l\nATP 0.3 mmol/l\nMg2+ 40 mmol/l\nNa-cholat 0.20 mmol/l\nPotassium-Hexacyanoferrat(II) 1 μmol/l

關聯藥證數量: 1

Pipes buffer：90 mmol/l\nPhenol：26 mmol/l\nCholesterol Oxidase：200 U/l\nCholesterol Esterase：300 U/l\nPeroxidase：1250 U/l\n4-Aminoantipyrine：0.4 mmol/l\n

關聯藥證數量: 1

Pipoxolan Hydrochloride contains NLT 98.0% and NMT 102.0% of C22H26ClNO3, calculated on the dried basis.

關聯藥證數量: 1

Piracetam contains not less than 98% and not more than 102% of C6H10N2O2,calculated with reference to the dried substance.

關聯藥證數量: 1

Piracetam contains not less than 98.0 and not more than 102% of C6H10N2O2,calculated on the dried substance.

關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2

關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2 calculated on the dried substance.

關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2, calculated on dried basis.

關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2, calculated on the dried substance.

關聯藥證數量: 1

Pirfenidone

關聯藥證數量: 1

Pirfenidone contains not less than 98.0 % and not more than 102.0% of C12H11NO, calculated on the dried substance.

關聯藥證數量: 1

Pirfenidone contains not less than 98.0% and not more than 102.0% of C12H11NO, calculated on dried substance.

關聯藥證數量: 1

Pirfenidone contains not less than 98.0% and not more than 102.0% of C12H11NO, calculated on the anhydrous basis.

關聯藥證數量: 1

Piroxicam contains not less than 97.0% and not more than 103.0% of C15H13N3O4S, calculated on the dried basis.

關聯藥證數量: 1

Piroxicam contains not less than 97.0% and not more than 103.0% of C15H13N3O4S.

關聯藥證數量: 1

Piroxicam contains not less than 98.5% not more than the equivalent of 101.0% of C15H13N3O4S, calculated with reference to the dried substance.

關聯藥證數量: 1

Pitavastatin Calcium Not less than 98.0% and not more than 102.0% w/w.

關聯藥證數量: 1

Pitavastatin Calcium (Hydrate) contains not less than 98.0% and not more than 102.0% of (C25H23 FNO4)2Ca, calculated on the anhydrous substance.

關聯藥證數量: 1

Pitavastatin Calcium (pentahydrate) contains not less than 98.0% and not more than 102.0% of (C25H23FNO4)2Ca・5H2O, calculated on the anhydrous basis.

關聯藥證數量: 1

Pitavastatin Calcium Hydrate (Pentahydrate) contains not less than 98.0% and not more than 102.0% of Pitavastatin Calcium (C50H46CaF2N2O8), calculated on the anhydrous basis.

關聯藥證數量: 1

Pitavastatin Calcium Hydrate 98.0%~102.0%(as anhydrous basis)

關聯藥證數量: 1

Pitavastatin Calcium Hydrate contains not less than 98.0% and not more than 102.0% of pitavastatin calcium (C50H46CaF2N2O8), calculated on the anhydrous basis.

關聯藥證數量: 1

Pitavastatin Calcium contains 98.0% ~ 102.0% of C50H46F2N2O8Ca calculated on anhydrous basis.

關聯藥證數量: 1

Pitavastatin Calcium contains not less than 98.0% and not more than 101.0% of (C25H23FNO4)2‧Ca, calculated on the anhydrous substance.

關聯藥證數量: 1

Pitavastatin calcium hydrate contains not less than 98.0% and not more than 102.0% of C50H46CaF2N2O8, calculated on the anhydrous basis.

關聯藥證數量: 1

Plasma N品管液是從健康的捐血者所取得的集合血漿. Plasma N品管液是用高純度的HEPES緩衝溶液(12g/L)加以保存並冷凍乾燥，所以很穩定. 但為避免因接觸而活化凝血系統，本包裝使用矽化物處理過的瓶子封裝. 另外，Plasma N品管液並未添加防腐劑。

關聯藥證數量: 1

Plasmin (human), lyophilized; concentration in the working solution: 0.1 CTA U/mLPlasmin Substrate, lyophilized; concentration in the working solution: D-Norvalyl-cyclohexylala-nyl-lysyl-p-nitroanilide (HD-Nva-CHA-Lys-CHA-pNA) 3 mmol/LBuffer solution: KH2PO4(100 mmol/L), NaCl (9 g/L), glycerol (250 g/L), pH7.5

關聯藥證數量: 1

Plastic Bag

關聯藥證數量: 1

Plastic Forceps\nPlastic Forceps, 2 per package.

關聯藥證數量: 1

Plastic manufacured vacuum blood collection tubes, silicone coated.

關聯藥證數量: 1

Plastinex, 20 x 4.0 ml

關聯藥證數量: 1

Plate: 96det. Microwell plate, 12 microwell strips in strip holder; coated with monoclonal antibodies against astroviruses\nDiluent: 100mL. Sample-dilution buffer, protein-buffered NaCl solution; contains 0.1% Kathon\nWash: 100mL. Wash buffer, phosphate-buffered NaCl solution (10-fold concentrate); contains 0.1% Thimerosal\nControl+: 1.8mL. Inactivated astroviruses\nConjugate: 10mL. Peroxidase-conjugated antibody in stabilized protein solution; contains 0.1% Kathon\nSubstrate: 10mL. Urea peroxide/TMB\nStop: 6mL. Stop reagent. 1N sulphuric acid

關聯藥證數量: 1

Plate： 12 microwell strips（can be divided）in the strip holder, coated with EBNA-1\nSeroPP：Sample buffer, phosphate-buffered NaCI solution；coloured yellow；contains 0.01% thimerosal and 0.05% tween 20\nSeroWP：Wash buffer, 10-fold concentrate；tris-buffered NaCI solusion；contains 0.2% bronidox-L and 0.5% tween 20\nControl IgG＋：Standard control IgG, diluted human serum；coloured green；contains 0.01% thimerosal and 0.05% tween 20\nControl IgG-：Negative control IgG, diluted human serum；contains 0.01% thimerosal and 0.05% tween 20 \nSeroG LD：Anti-human IgG conjugate（goat）, peroxidase conjugated antibodies in stabilised protein solution；contains 10 ppm proclin, 0.01 % methylisothiazolinone, 0.01 % bromonitrodioxane. \nSeroSC：Substrate；H2O2/tetramethylbenzidine\nSeroStop：Stop reagent0.5 M sulphuric acid

關聯藥證數量: 1

Plectranthus amboinicus extract - F4

關聯藥證數量: 1

Plectranthus amboinicus extract fraction 4 contains 0.159% ~ 0.265% of salvigenin.±

關聯藥證數量: 1

Pneumococcal antisera are raised in rabbits. Each vial contains 1ml antiserum preserved with 15 mM sodium azide.

關聯藥證數量: 1

Pneumoslide Streptococcus pneumoniae Antibody-Coated Latex Bead Suspension (2.5 mL) is a 1% suspension of latex beads with rabbit antibody specific for S. pneumoniae capsular antigens in glycine buffer. \nPneumoslide Polyvalent Positive Control. \nPneumoslide Latex Negative Control.

關聯藥證數量: 1

Policresulen 50% solution contains not less than 45% w/w and not more than 55% w/w of C23H24O12S3.

關聯藥證數量: 1

Policresulen 50% solution contains not less than 45.0% w/w and not more than 55.0% of C23H24O12S3

關聯藥證數量: 1

Policresulen solution contains not less than 45.5% w/w and not more than 54.5% w/w of C23H24O12S3.

關聯藥證數量: 1

Poloxame

關聯藥證數量: 1

Poloxamer

關聯藥證數量: 1

Poloxamer 407

關聯藥證數量: 1

Polyaminopropyl Biguanide (20%)

關聯藥證數量: 1

Polyaminopropyl Biguanide Solution 20% w/w (PAPB Hydrochloride 20% w/w).....0.00779＊\nBoric Acid.....6.4\nSodium Borate.....0.9\nEdetate Disodium.....1.1＊＊\nSodium Chloride.....4.9\nPoloxamine 1107.....10.0\nHydroxyalkylPhosphonate (30%).....1.0\nHydrochloric Acid, 1N.....As needed (pH)\nSodium Hydroxide, 1N.....As needed (pH)\nPurified Water, 1N.....1.0\n＊Includes a 18% manufacturing overage\n＊＊Includes a 10% manufacturing overage\n以下空白

關聯藥證數量: 1

Polyethylene Glycol 400

關聯藥證數量: 1

Polyethylene Glycol Mono-p-isooctylphenyl Ether\n(Triton X-100)\nSodium azide\nSodium phosphate tribasic dodecahydrate

關聯藥證數量: 1

Polyhexamethyl Biguanide Solution 20% w/w（PAPB Hydrochloride20% w/w)..........0.0047mg\nBoric Acid..........................6.4mg\nEdetate Disodium...............1.1mg\nSodium Chloride.................4.9mg\nPoloxamine........................10.0mg\nHydrochloric Acide1N..........As needed(pH)\nSodium Hydroxide 1N..........As needed(pH)\nPurified Water 1N...........qs.to1.0ml\n以下空白\n\n

關聯藥證數量: 1

Polyhexamethylene Biguanide (PHMB)

關聯藥證數量: 1

Polyhexamethylene Biguanide Hydrochloride Solution 20% (Cosmocil CQ) (PHMB)

關聯藥證數量: 1

Polyhexamethylene Biguanide Hydrochloride Solution 20% (Cosmocil CQ) (PHMB)

關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0015 mg/ml\nEdetate. 2Na.....0.5 mg/ml\nPoloxamer.....0.5 mg/ml \nHydroxypropyl Methylcellulose.....1.2 mg/ml\nBoric acid.....8.233 mg/ml\nBorax......0.9 mg/ml\nSodium chloride.....4.56 mg/ml\nWater for purification.....q.s. to 1 ml\n以下空白

關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0018 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....1.0 mg/ml;\nHPMC.....1.2 mg/ml;\nGlycerine.....2.0 mg/ml;\nMenthol.....0.004 mg/ml;\nBoric acid.....6.4 mg/ml;\nBorax.....0.9 mg/ml;\nSodium chloride.....5.0 mg/ml;\nPurified Water.....q.s. to 1 ml \n以下空白

關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0018 mg/ml\nEdetate. 2Na.....0.5 mg/ml\nPoloxamer.....2.0 mg/ml \nHydroxypropyl Methylcellulose.....0.6 mg/ml\nBoric acid.....6.4 mg/ml\nBorax.....0.9 mg/ml\nSodium chloride.....5.5 mg/ml\nWater for purification.....q.s. to 1 ml \n以下空白

關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0018 mg/ml\nEdetate. 2Na.....0.5 mg/ml\nPoloxamer.....2.0 mg/ml \nHydroxypropyl Methylcellulose.....1.2 mg/ml\nGlycerine.....2.0 mg/ml\nBoric acid.....6.4 mg/ml\nBorax.....0.9 mg/ml\nSodium chloride.....4.6 mg/ml\nPotassium chloride.....0.4 mg/ml\nWater for purification.....q.s. to 1 ml \n以下空白

關聯藥證數量: 1

Polyhexamethylene biguanide hydrochloride

關聯藥證數量: 1

Polyhexamethylene biguanide, PHMB

關聯藥證數量: 1

Polyhexamethylene biquanide (PHMB).....0.0015 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....2.0 mg/ml; \nPovidone K30.....0.118 mg/ml;\nBoric acid.....6.4 mg/ml;\nBorax.....0.9 mg/ml;\nSodium chloride.....6.0 mg/ml;\nPurified Water.....q.s. to 1 ml; \n以下空白

關聯藥證數量: 1

Polyhexamthylene biguanide(PHMB).....0.0018mg/ml\nBoric acid.....6.4mg/ml\nSodium borate.....0.9mg/ml\nSodium chloride.....6mg/ml\nEdetate.2Na.....0.5mg/ml\nPoloxamer.....1mg/ml\nHPMC.....0.7mg/ml\nWater for purification.....q.s.to 1ml \n以下空白

關聯藥證數量: 1

Polyhexamthylene biquanide (PHMB)..... 0.0015 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....0.5 mg/ml;\nHPMC..... 1.2 mg/ml;\nBoric acid.....6.4 mg/ml;\nBorax..... 0.9 mg/ml;\nSodium chloride..... 3.6 mg/ml;\nPotassium chloride.....0.4 mg/ml;\nWater for purification..... q.s. to 1 ml\n以下空白

關聯藥證數量: 1

Polyhexamthylene biquanide (PHMB).....0.0018 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....2 mg/ml;\nHPMC.....1.2 mg/ml;\nPropylene glycol.....2.0 mg/ml;\nSodium Hyaluronate.....0.05 mg/ml;\nBoric acid.....15 mg/ml;\nDisodium Hydrogen Phosphate.....0.24 mg/ml;\nSodium chloride.....1.2 mg/ml;\nPotassium chloride.....0.5 mg/ml;\nWater for purification..... q.s. to 1 ml\n以下空白 \n

關聯藥證數量: 1

Polyhexanide.....0.001mg\nPoloxamer 188.....1mg\nDisodium Edetate.....0.5mg\nDisodium Phosphate Anhydrous.....1.015mg\nSodium Chloride.....8.75mg\nSodium Dihydrogen Phosphate Dihydrate.....0.38mg\nPurified Water q.s. to.....1ml\n以下空白\n

關聯藥證數量: 1

Polymigel (CO-PPT of Al(OH)3：CaCO3：MgCO3=2：2：1) contains 19.5%~24.5% of Al2O3, and 9.5%~14.5% of MgO, and 21.5%~26.5% of CaO, on the dried basis.

關聯藥證數量: 1

Polyoxy40

關聯藥證數量: 1

Polyoxyethylene Polyoxypropylene Block Copolymer (Poloxamer 407)

關聯藥證數量: 1

Polyquaternium-1

關聯藥證數量: 1

Polyquaternium-1(Polyquad).....0.01mg;\nAL-6289(N[3-Dimethylamino]propyl) tetradecanamide.....0.006mg+up to 7% excess;\nEOBO-41TM-polyoxyethylene-polyoxybutylene.....0.4mg;\nTetronic 1304 (poloxamine).....0.4mg;\nSorbitol.....12.0mg;\nBoric Acid.....6.0mg;\nSodium citrate.....6.5mg;\nSodium Chloride.....1.0mg;\nDisodium EDTA (edentate disodium).....0.5mg;\nUltra Pure AMP(2-amino-2methyl-1-propanol).....4.2mg;\nSodium hydroxide and/or Hydrochloric acid pH adjust to 7.8;\nPurified water Q.S 以下空白\n\n\n\n\n

關聯藥證數量: 1

Polysaccharide Iron Complex is a combination of saccharide and iron. It contains not less than 44.5% and not more than 47.5% of iron.

關聯藥證數量: 1